Actinogen Medical Ltd (acw) Logo

Actinogen Medical Ltd (ACW)

___:___ · Healthcare

ACW Chart


ACW's Principal Activity is the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -20.25%
vs ASX 200 (1yr) -27.49%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 921 of 2,413
Sector Rank 64 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies CYC / ONE / EOF
EPS -$0.005
DPS $0.00
Book Value Per Share $0.01

Broker Consensus

ACW is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Actinogen Medical Limited (ACW, formerly Actinogen Limited) is an ASX-listed biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. It focusses on the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases within Australia.

Incorporation Details

Incorporated Actinogen Limited was incorporated on 26/03/1999 in Western Australia.

Corporate Details

Head Office Sydney NSW 2000
Registry Automic Group
Auditor Ernst & Young
Date Listed 16 Oct 2007

Upcoming Calendar (Forecasted)

Date Event
29/08/2022 Report (Prelim)
29/08/2022 Report (Annual)
07/10/2022 Report (Annual)
23/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Steven Gourlay Chief Executive Officer,Managing Director Mar 2021

Dr Steven Gourlay

Chief Executive Officer,Managing Director

Dr Gourlay has more than 30 years of experience in the development of novel therapeutics and brings skills and experience to Actinogen as the Company moves into further clinical development of its lead compound Xanamem. Formerly the founding Chief Medical Officer (CMO) at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, Phase 2 and 3 clinical trial programs in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay's roadshow presentations, supported a successful NASDAQ IPO of Principia Biopharma Inc. in 2018 - subsequently followed by an acquisition by Sanofi for US$3.7 billion in 2020. Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, the Australian specialist life sciences and healthcare venture capital firm, where he contributed to the success of multiple clinical stage therapeutic companies including Elastagen, Spinifex and Peplin. Before GBS, and after a post doctorate in clinical pharmacology at the University of California, San Francisco, he held positions of increasing responsibility at Genentech, Inc. in the areas of pharmacoepidemiology and early clinical development. Dr Gourlay has drug regulatory experience with the US Food and Drug Administration (FDA), European Medicines Agency (EMA) at many levels, including filing more than 10 Investigational New Drug (IND) applications, achieving several orphan drug status approvals for his Company's product(s), and completing several biologics license applications.

Dr Geoffrey E.D Brooke Non-Executive Chairman,Non-Executive Director Feb 2021

Dr Geoffrey E.D Brooke

Non-Executive Chairman,Non-Executive Director

Dr Brooke have more than 30 years international experience as the founder, lead investor and/or Chairman/Director of numerous healthcare companies with a realised value of more than $1.5 billion. Most notably, he was the Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures - one of Asia Pacific's premier investors in the healthcare space. There, Dr Brooke was responsible for GBS's healthcare venture activity in the region and raised $450 million in venture and private equity funds, focused on biopharmaceuticals, medical devices and services. Dr Brooke was also responsible for numerous investments and exits via NASDAQ and ASX public listings and trade sales, as well as being lead investor in numerous investments syndicated in multiple rounds with premier US venture firms. Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc., with investors including the venture capital arm of leading global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Medvest was focused on founding companies based upon healthcare-related technology, including pharmaceuticals, biotechnology, therapeutic devices, medical services and information systems. Dr Brooke now acts as a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies.

Mr Malcolm John McComas Non-Executive Director Apr 2019

Mr Malcolm John McComas

Non-Executive Director

Mr McComas is a company director with experience in healthcare including drug development, clinical trials, the regulatory environment and medical devices. He was previously an investment banker with career experience in financial services covering mergers and acquisitions, debt and equity funding across multiple industry sectors including healthcare, FMCG, resources, financial services and privatisations. He has held leadership roles with Grant Samuel as Director, County NatWest (now Citigroup) as Managing Director and Head of Corporate Finance and Morgan Grenfell (now Deutsche Bank) working in Australia and the UK. Previously, Mr McComas was a lawyer at Herbert Geer specialising in tax and company law. He has for-purpose experience as a director of Australasian Leukaemia and Lymphoma Group (ALLG), the blood cancer clinical trials group and peak body experience as past President of the Financial Services Institute of Australia.

Dr George Morstyn Non-Executive Director Dec 2017

Dr George Morstyn

Non-Executive Director

Dr Morstyn has more than 25 years experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had overall responsibility globally for drug development in all therapeutic areas including neuroscience at Amgen Inc. and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn's tenure. Prior to joining Amgen Inc. Dr Morstyn was the principal investigator on the earliest clinical studies of the haemopoietic colony stimulating factors (CSF). The CSFs were subsequently approved and launched and were a major medical breakthrough that have been used to reduce side effects of chemotherapy and enable transplantation in more than 20 million patients worldwide. The CSFs have become multi-billion dollar drugs. Since returning to Australia, Dr Morstyn has been a Non-Executive Director of various for-profit and not-for-profit companies, including many biotechnology companies. He is currently an advisor to Symbio (Tokyo) Limos Biotech and TroBio.

Mr Peter Webse Company Secretary N/A
Jeff Carter Chief Financial Officer N/A
Tamara Miller Vice President of Drug Development & Strategy N/A

Director Transactions

ACW directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
12/05/22 Steven Gourlay Buy +2,000,000 $0.064 $128,240 On-market trade
06/04/22 Steven Gourlay Issued 797,222 $0.135 $107,624 Placement
20/12/21 Malcolm McComas Issued 222,223 $0.135 $30,000 Participation in share purchase plan
20/12/21 George Morstyn Issued 222,223 $0.135 $30,000 Participation in share purchase plan
20/12/21 Geoffrey Brooke Issued 222,223 $0.135 $30,000 Participation in share purchase plan
18/11/21 Geoffrey Brooke Issued 2,500,000 $0.20 $500,000 Issued under employee share plan
18/11/21 George Morstyn Issued 1,000,000 $0.20 $200,000 Issued under employee share plan
18/11/21 Malcolm McComas Issued 1,000,000 $0.20 $200,000 Issued under employee share plan
17/11/20 Malcolm McComas Issued 100,000 $0.022 $2,200 Rights issue
17/11/20 George Morstyn Issued 40,000 $0.022 $880 Rights issue
17/11/20 John (Bill) Ketelbey Issued 1,862,182 $0.022 $40,968 Rights issue
17/11/20 John (Bill) Ketelbey Issued 128,579 $0.022 $2,828 Rights issue
17/11/20 Geoffrey Brooke Issued 265,000 $0.022 $5,830 Rights issue
31/01/20 John (Bill) Ketelbey Cancelled 3,000,000 $0.035 $105,000 Cancellation of securities
22/11/19 John (Bill) Ketelbey Transfer 9,000,000 $0.05 $450,000 As advised by the company
22/11/19 John (Bill) Ketelbey Transfer 9,000,000 $0.05 $450,000 As advised by the company

Director Interests

The current holdings of ACW directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Steven Gourlay 12/05/2022 50,362,300 15,797,222 N/A N/A
Geoffrey Brooke 20/12/2021 2,500,000 1,812,223 9,900,000 N/A
Malcolm McComas 20/12/2021 N/A 1,822,223 3,000,000 N/A
George Morstyn 20/12/2021 1,222,223 2,790,000 3,000,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 24, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 249,813,605 15.04%
Dr Steven Gourlay 48,362,300 2.91%
Edinburgh Technology Fund Limited 48,147,864 2.90%
JSC Wealth Management Pty Ltd 44,655,962 2.69%
Tisia Nominees Pty Ltd <Henderson Family A/C> 33,440,621 2.01%
Citicorp Nominees Pty Limited 19,464,401 1.17%
Garnsworthy Pension Fund Pty Ltd <Garnsworthy Pension Fund A/C> 16,500,000 0.99%
Big Eater Pty Ltd <Brigitte Smith Family A/C> 15,000,000 0.90%
Mr James Murch & Mrs Catherine Murch <MINJAL Super Fund A/C> 15,000,000 0.90%
SG Gourlay Nominees Pty Ltd <SF Gourlay Family A/C> 15,000,000 0.90%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C> 13,247,438 0.80%
Mrs Gillian Karen Nes & Mrs Ronald Nes <GIRO S/F A/C> 13,000,000 0.78%
Surfit Capital Pty Ltd 12,500,000 0.75%
Oaktone Nominees Pty Ltd <Grist Investment A/C> 12,000,000 0.72%
Brazil Farming Pty Ltd 12,000,000 0.72%
Double Jay Group Holdings Pty Ltd <Kimberley S/F A/C> 11,475,253 0.69%
National Nominees Limited 11,282,894 0.68%
Amber Court Nominees Pty Ltd <Min Light A/C> 11,265,203 0.68%
Kaleidoscope Holdings Pty Ltd <Kaleidoscope Super A/C> 10,800,000 0.65%
John Dahlsen Superannuation Fund Pty Ltd 10,411,036 0.63%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 87 256 494 2,239 1,375 4,451

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
BVF Partners L.P 24/08/2021 239,927,273 14.88

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.125 30 June
2020 $0.022 30 June
2019 $0.01 28 June
2018 $0.048 29 June
2017 $0.061 28 June
2016 $0.072 28 June
2015 $0.072 30 June
2014 $0.011 30 June
ACW Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.